(Q36830126)

English

Ranibizumab

scientific article published on January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

Europe PubMed Central

Ranibizumab. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Antona J Wagstaff

3

object named as

Antona J Wagstaff

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Gillian M Keating

2

object named as

Gillian M Keating

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

author name string

Stephanie K A Blick

1

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

publication date

1 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

67

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1199-206; discussion 1207-9

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

New pharmacologic approaches to therapy for age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegaptanib for neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Wet age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current and future treatment options for nonexudative and exudative age-related macular degeneration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab: Phase III clinical trial results

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17521219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200767080-00007

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36830126&oldid=2199405669"